<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30058895</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8417</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>09</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Expert review of endocrinology &amp; metabolism</Title>
                <ISOAbbreviation>Expert Rev Endocrinol Metab</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>289-301</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/17446651.2017.1347501</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION">Extended-release calcifediol (ERC) 30Â Âµg capsules were recently approved as RayaldeeÂ® by the United States Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3-4 (not 5) chronic kidney disease (CKD) and vitamin D insufficiency (serum total 25-hydroxyvitamin DÂ &lt;Â 30Â ng/mL). Calcifediol is 25-hydroxyvitamin D<sub>3</sub>, a prohormone of calcitriol (1,25-dihydroxyvitamin D<sub>3</sub>), the endogenous active vitamin D hormone. ERC capsules have a lipophilic fill which gradually releases calcifediol, corrects vitamin D insufficiency and increases serum calcitriol and thereby suppresses production of parathyroid hormone (PTH) in CKD patients without perturbing normal vitamin D and mineral metabolism. Areas covered: This review focuses on the chemical, pharmacokinetic, pharmacodynamic and clinical profiles of ERC and describes the product's utility relative to other current treatment options for SHPT. Expert commentary: Randomized clinical trials (RCTs) have demonstrated that nutritional vitamin D is ineffective for treating SHPT whereas vitamin D receptor activators can correct elevated PTH but with increased risk of hypercalcemia and hyperphosphatemia. ERC offers healthcare professionals a new treatment option that has been demonstrated in RCTs to be safe and effective for controlling SHPT without meaningfully increasing serum concentrations of calcium or phosphorus.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sprague</LastName>
                    <ForeName>Stuart M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Medicine , NorthShore University HealthSystem , Evanston , IL , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strugnell</LastName>
                    <ForeName>Stephen A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Renal Division , OPKO Health, Inc ., Miami , FL , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bishop</LastName>
                    <ForeName>Charles W</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Renal Division , OPKO Health, Inc ., Miami , FL , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Rev Endocrinol Metab</MedlineTA>
            <NlmUniqueID>101278293</NlmUniqueID>
            <ISSNLinking>1744-6651</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">25-hydroxyvitamin D3</Keyword>
            <Keyword MajorTopicYN="Y">Chronic kidney disease</Keyword>
            <Keyword MajorTopicYN="Y">calcifediol</Keyword>
            <Keyword MajorTopicYN="Y">parathyroid hormone</Keyword>
            <Keyword MajorTopicYN="Y">secondary hyperparathyroidism</Keyword>
            <Keyword MajorTopicYN="Y">vitamin D</Keyword>
            <Keyword MajorTopicYN="Y">vitamin D insufficiency</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30058895</ArticleId>
            <ArticleId IdType="doi">10.1080/17446651.2017.1347501</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>